Cardiac hypertrophy with heart failure requires active treatment of the primary disease, anti-heart failure therapy, and non-pharmacological treatment. Cardiac hypertrophy is the enlargement or hypertrophy of the chambers of the ventricles and atria, including hypertrophic cardiomyopathy and dilated cardiomyopathy. Structural changes in the heart can cause a decline in heart function and trigger heart failure. Heart failure also includes acute heart failure, chronic heart failure and total heart failure. 1. Active treatment of hypertrophic cardiomyopathy or dilated cardiomyopathy can help improve heart failure symptoms. Hypertrophic cardiomyopathy can be treated with beta-receptor antagonists (metoprolol, etc.) to reduce ventricular outflow through obstruction and delay ventricular remodeling. Dilated cardiomyopathy can actively control the infection and use β-receptor antagonists (metoprolol, etc.) to slow down ventricular remodeling. 2. Aggressive anti-heart failure therapy includes the use of diuretics (furosemide, hydrochlorothiazide, etc.), angiotensin-converting enzyme inhibitors (captopril, etc.), β-receptor antagonists (metoprolol, etc.), and digitalis analogs (molluscum tosylate, etc.). 3. Non-pharmacological treatments include heart transplantation, extracorporeal membrane oxygenation (ECMO), and intra-aortic balloon counterpulsation. In case of cardiac hypertrophy with heart failure, it is recommended to consult a doctor in time and standardize the treatment, and the drugs should be used under the guidance of a professional doctor.